Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon 25000 for Steatorrhea in HIV-infected Patients
NCT00623025Phase 3Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jan 2009
- Primary completion
- Aug 2009
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LipaCreon in steatorrhea (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Coefficient of fat absorption at 2 weeks. Started Jan 2009; status: terminated.
02
Drugs
LipaCreon
03
Conditions
steatorrhea
Beyond the preview
Go deeper on NCT00623025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623025.